Plus Therapeutics (NASDAQ:CNSY) Stock Falls 4.1% – Should You Sell?

Plus Therapeutics, Inc. (NASDAQ:CNSY)’s stock price traded down 4.1% during mid-day trading on Friday. The stock traded as low as $0.6001 and last traded at $0.6427. 508,717 shares changed hands during trading, an increase of 579% from the average daily volume of 74,870 shares. The stock had previously closed at $0.6699.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Zacks Research lowered Plus Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Monday, November 2nd. Two equities research analysts have rated the stock with a Sell rating. According to MarketBeat, the company presently has a consensus rating of “Sell”.

Plus Therapeutics Stock Down 4.1%

The firm has a fifty day moving average price of $1.92. The stock has a market capitalization of $4.88 million, a PE ratio of -0.19 and a beta of 1.49.

Plus Therapeutics (NASDAQ:CNSY) last issued its quarterly earnings data on Friday, August 14th. The company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.35). The firm had revenue of $0.41 million for the quarter. Plus Therapeutics had a negative net margin of 620.70% and a negative return on equity of 394.17%. As a group, research analysts expect that Plus Therapeutics, Inc. will post -4.40 earnings per share for the current year.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. Its lead investigational product is Rhenium-186 NanoLiposome (RNL), a proprietary formulation designed to deliver the radioactive isotope rhenium-186 directly to tumors while limiting exposure to surrounding healthy tissue.

The company has focused its development programs primarily on central nervous system cancers, including recurrent glioblastoma and leptomeningeal metastases.